New phase I clinical trial involving a polymeric nanoparticle formulation of docetaxel


Korean company Samyang started in April 2010 a phase I clinical trial involving a polymeric nanoparticle formulation of docetaxel, now registered in the Clinicaltrials.gov database under reference NCT01103791. According to this page, the aim is to “determine the maximum tolerated dose and recommended phase II dose of docetaxel-PNP (polymeric nanoparticle formulation of docetaxel) and to evaluate the safety and pharmacokinetics of docetaxel-PNP in subjects with advanced solid malignancies“.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: